哌拉西林钠/他唑巴坦钠治疗支气管扩张合并铜绿假单胞菌感染效果

The Effect of Piperacillin Sodium/Tazobactam Sodium in the Treatment of Bronchiectasis Complicated by Pseudomonas Aeruginosa Infection

目的探讨哌拉西林钠/他唑巴坦钠治疗支气管扩张合并铜绿假单胞菌感染效果。方法选取2012年1月—2016年12月诊断为支气管扩张合并铜绿假单胞菌感染入我院治疗的患者192例作为研究对象,将其随机分为治疗组(哌拉西林钠/他唑巴坦钠4.5 g,3次/天,静滴)与对照组(阿莫西林钠/克拉维酸钾1.2 g,3次/天,静滴),疗程均10~14 d。对比两组患者的治疗效果。结果治疗组的总有效率91.7%,高于对照组(75.0%),差异有统计学意义(z=2.980,P=0.003);治疗组患者的不良反应发生率3.13%,低于对照组(4.17%),差异无统计学意义(χ2=0.194,P=0.659)。结论哌拉西林钠/他唑巴坦钠对支气管扩张合并铜绿假单胞菌感染的临床疗效好,不良反应少。

Objective To investigate the efficacy of piperacillin sodium/ tazobactam sodium in the treatment of bronchiectasis complicated with pseudomonas aeruginosa infection. Methods 192 cases from January 2012 to December 2016 who were diagnosied bronchiectasis complicated with pseudomonas aeruginosa infection were randomly divided into treatment group （piperacillin sodium/tazobactam sodium, 4.5 g, 3 times/day, intravenous drip） and control group （amoxicillin sodium/clavulanate potassium, 1.2 g, 3 times/day intravenous drip）, the treatment lasted for 10-14 d. The therapeutic effects of the two groups were compared. Results The total effective rate of the treatment group was 91.7%, higher than that of the control group （75.0%）, and the difference was statistically significant （z=2.980, P=0.003）. The incidence of adverse reactions in the treatment group was 3.13%, which was lower than that in the control group （4.17%）, and the difference was not statistically significant （Z2=0.194, P=0.659）. Conclusion Piperacillin sodium/tazobactam sodium is effective and less harmful in the treatment of bronchiectasis combined with pseudomonas aeruginosa infection.